Intracranial Hemorrhage in Patients with Anticoagulant Therapy Undergoing Stereotactic Radiosurgery for Brain Metastases: A Bi-Institutional Analysis
Authors:
Open Access
Abstract
Background: Stereotactic radiosurgery (SRS) is a well-established treatment modality for brain metastases (BM). Given the manifold implications of metastatic cancer on the body, affected patients have an increased risk of comorbidities, such as atrial fibrillation (AF) and venous thromboembolism (VTE), which includes pulmonary embolism (PE) and deep-vein thrombosis (DVT). These may require therapeutic anticoagulant therapy (ACT). Limited data are available on the risk of intracranial hemorrhage (ICH) after SRS for patients with BM who are receiving ACT. This bi-institutional analysis aimed to describe the bleeding risk for this patient subgroup. Methods: Patients with ACT at the time of single-fraction SRS for BM from two institutions were eligible for analysis. The cumulative incidence of ICH with death as a competing event was assessed during follow-up with magnetic resonance imaging or computed tomography. Results: Forty-one patients with 97 BM were included in the analyses. The median follow-up was 8.2 months (range: 1.7–77.5 months). The median and mean BM volumes were 0.47 and 1.19 cubic centimeters, respectively. The most common reasons for ACT were PE (41%), AF (34%), and DVT (7%). The ACT was mostly performed utilizing phenprocoumon (37%), novel oral anticoagulants (32%), or low-molecular-weight heparin (20%). Nine BM from a group of five patients with ICH after SRS were identified: none of them caused neurological or any other deficits. The 6-, 12-, and 18-month cumulative bleeding incidences per metastasis were 2.1%, 12.4%, and 12.4%, respectively. The metastases with previous bleeding events and those originating from malignant melanomas were found to more frequently demonstrate ICH after SRS (p = 0.02, p = 0.01). No surgical or medical intervention was necessary for ICH management, and no observed death was associated with an ICH. Conclusion: Patients receiving an ACT and single-fraction SRS for small- to medium-sized BM did not seem to have a clinically relevant risk of ICH. Previous bleeding and metastases originating from a malignant melanoma may favor bleeding events after SRS. Further studies are needed to validate our reported findings.Keywords
This publication has 50 references indexed in Scilit:
- Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with brain metastasesMelanoma Research, 2012
- Fatal tumoral hemorrhage after stereotactic radiosurgery for metastatic brain tumors: report of three cases and review of literatureActa Neurochirurgica, 2012
- Vestibular Schwannomas presenting with haemorrhage: Clinical presentation and histopathological evaluation of an unusual entityBritish Journal Of Neurosurgery, 2009
- Intracochlear Hemorrhage After Gamma Knife RadiosurgeryOtology & Neurotology, 2007
- Fatal Intratumoral Hemorrhage Immediately after Gamma Knife Radiosurgery for Brain Metastases: Case Reportmin - Minimally Invasive Neurosurgery, 2006
- Intracerebral Hemorrhage Associated With Oral Anticoagulant TherapyStroke, 2006
- Current Management of Brain Metastases, With a Focus on Systemic OptionsJournal of Clinical Oncology, 2005
- Incidence Proportions of Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance SystemJournal of Clinical Oncology, 2004
- Spontaneous haemorrhage into metastatic brain tumours after stereotactic radiosurgery using a linear acceleratorJournal of Neurology, Neurosurgery & Psychiatry, 2003
- Therapy of venous thromboembolism in patients with brain metastasesCancer, 1994